litlas
ログインアカウント作成

Kim Papp

1999–2025 年に発表

240
論文数
44,425
被引用数
107
h 指数
225
i10 指数

被引用数

Kim Papp の年別被引用数1964 年: 被引用 1 件1984 年: 被引用 1 件1986 年: 被引用 1 件1998 年: 被引用 10 件2001 年: 被引用 2 件2002 年: 被引用 10 件2003 年: 被引用 52 件2004 年: 被引用 48 件2005 年: 被引用 80 件2006 年: 被引用 99 件2007 年: 被引用 136 件2008 年: 被引用 138 件2009 年: 被引用 200 件2010 年: 被引用 185 件2011 年: 被引用 247 件2012 年: 被引用 275 件2013 年: 被引用 359 件2014 年: 被引用 345 件2015 年: 被引用 386 件2016 年: 被引用 469 件2017 年: 被引用 714 件2018 年: 被引用 697 件2019 年: 被引用 1,970 件2020 年: 被引用 1,970 件2021 年: 被引用 1,895 件2022 年: 被引用 1,565 件2023 年: 被引用 1,586 件2024 年: 被引用 1,956 件2025 年: 被引用 1,121 件2026 年: 被引用 9 件1965〜1983 年は被引用が無いため表示していません1985 年は被引用が無いため表示していません1987〜1997 年は被引用が無いため表示していません1999〜2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,151 件、この内訳の 22.4%ドイツ: 引用元論文 1,124 件、この内訳の 8%イギリス: 引用元論文 1,003 件、この内訳の 7.1%カナダ: 引用元論文 934 件、この内訳の 6.7%イタリア: 引用元論文 810 件、この内訳の 5.8%中国: 引用元論文 716 件、この内訳の 5.1%フランス: 引用元論文 610 件、この内訳の 4.3%日本: 引用元論文 561 件、この内訳の 4%スペイン: 引用元論文 474 件、この内訳の 3.4%オランダ: 引用元論文 448 件、この内訳の 3.2%スイス: 引用元論文 438 件、この内訳の 3.1%デンマーク: 引用元論文 344 件、この内訳の 2.5%
0%22.4%その他 24.4%

機関

分野

  • Medicine49.4%
  • Immunology and Microbiology37.6%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Neuroscience3.7%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Psychology0.3%
  • その他1.4%

トピック

  • Psoriasis: Treatment and Pathogenesis16.5%
  • Dermatology and Skin Diseases12.9%
  • Spondyloarthritis Studies and Treatments7.4%
  • Asthma and respiratory diseases4%
  • Rheumatoid Arthritis Research and Therapies3.9%
  • Allergic Rhinitis and Sensitization3.4%
  • その他51.9%

共著者

全論文

検索で開く
  1. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    著者: Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel - The Lancet 2017 被引用: 1,243

  2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    著者: Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine - The Lancet 2021 被引用: 543

  3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

    著者: April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt - Journal of the American Academy of Dermatology 2022 被引用: 347

  4. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    著者: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 被引用: 1,964

  5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

    著者: Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim Papp - Journal of the American Academy of Dermatology 2022 被引用: 279

  6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    著者: Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball - Journal of the American Academy of Dermatology 2017 被引用: 860

  7. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    著者: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 被引用: 838

  8. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    著者: Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez - The Lancet 2018 被引用: 662

  9. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

    著者: Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb, Kim Papp, Christos C. Zouboulis, April W. Armstrong, Francisco A. Kerdel, Michael H. Gold, Seth Forman, Neil J. Korman, Evangelos J. Giamarellos‐Bourboulis, Jeffrey Crowley, Charles Lynde, Z. Reguiaï, Errol-Prospero Prens, Eihab Alwawi, Nael M. Mostafa, Brett Pinsky, Murali Sundaram, Yihua Gu, Dawn M. Carlson, Gregor B. E. Jemec - New England Journal of Medicine 2016 被引用: 777

  10. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    著者: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 被引用: 556

  11. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    著者: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 被引用: 297

  12. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

    著者: Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Donald Y.M. Leung, Seth Forman, May E. Venturanza, Kang Sun, Michael E. Kuligowski, Eric L. Simpson - Journal of the American Academy of Dermatology 2021 被引用: 297

  13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    著者: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 被引用: 669

  14. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    著者: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 被引用: 806

  15. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

    著者: Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee - New England Journal of Medicine 2018 被引用: 414

  16. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    著者: Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan, Hwanhee Hong, Kim Papp, Kristian Reich, Lisa A. Beck, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, J. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg - Journal of Allergy and Clinical Immunology 2019 被引用: 357

  17. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

    著者: Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula - New England Journal of Medicine 2017 被引用: 511

  18. Bimekizumab versus Adalimumab in Plaque Psoriasis

    著者: Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich - New England Journal of Medicine 2021 被引用: 238

  19. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    著者: Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon - The Lancet 2008 被引用: 1,865

  20. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

    著者: Mark Lebwohl, Linda Stein Gold, Bruce Strober, Kim Papp, April W. Armstrong, Jerry Bagel, Leon Kircik, Benjamin D. Ehst, Hwanhee Hong, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, Anna M. Tallman, Robert Bissonnette - New England Journal of Medicine 2021 被引用: 178

  21. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

    著者: Philip J. Mease, Apinya Lertratanakul, J. Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilová, Mauro Waldemar Keiserman, Xin Wang, Sheng Zhong, R. Mccaskill, Patrick Zueger, Aileen L. Pangan, William Tillett - Annals of the Rheumatic Diseases 2020 被引用: 233

  22. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

    著者: Eric L. Simpson, Kim Papp, Andrew Blauvelt, Chia‐Yu Chu, Hwanhee Hong, Norito Katoh, Brian Calimlim, Jacob P. Thyssen, Albert S. Chiou, Robert Bissonnette, Linda Stein Gold, Colleen Wegzyn, Xiaofei Hu, Meng Liu, John Liu, Allan R. Tenorio, Alvina D. Chu, Emma Guttman‐Yassky - JAMA Dermatology 2022 被引用: 204

  23. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    著者: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 被引用: 1,350

  24. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    著者: C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp - The Lancet 2015 被引用: 831